[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nkt-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nkt-cell-lymphoma":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,76,100,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100631598","phase-1-tislelizumab-plus-zeprumetostat-for-relapsed-or-refractory-nkt-cell-lymphoma-100631598",false,"NCT07502768","Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK\u002FT-Cell Lymphoma","A Multicenter, Open-Label, Seamless Phase Ib\u002FII Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Zeprumetostat (SHR2554) in Patients With Relapsed or Refractory NK\u002FT-Cell Lymphoma","EpiRev-NKT","Inclusion Criteria:\n\n* Age 18 years or older.\n* Pathologically confirmed NK\u002FT-cell lymphoma.\n* Relapsed or refractory disease after at least 1 prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy.\n* At least 1 measurable or evaluable lesion according to Lugano 2014 criteria.\n* ECOG performance status 0 to 2.\n* Life expectancy greater than 12 weeks.\n* Adequate hematologic, hepatic, renal, coagulation, and cardiac function.\n* Recovery from prior anti-cancer treatment-related toxicities to CTCAE grade 1 or baseline, except for specified stable irreversible toxicities allowed by the investigator.\n* Negative pregnancy test for women of childbearing potential.\n* Willingness to use effective contraception.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Prior treatment with any EZH1\u002F2 or EZH2 inhibitor.\n* Allogeneic hematopoietic stem cell transplantation within 5 years before study treatment.\n* Autologous hematopoietic stem cell transplantation within 3 months before study treatment.\n* Requirement for high-dose systemic corticosteroids or other immunosuppressive therapy within 14 days before study treatment, except permitted local\u002Finhaled or short-course use.\n* Cytotoxic chemotherapy not discontinued within 14 days before study treatment.\n* Systemic anti-cancer therapy or investigational therapy within 4 weeks before study treatment.\n* Major surgery within 4 weeks or radiotherapy within 90 days before study treatment.\n* Active infection, including active\u002Flatent tuberculosis, HIV infection, active hepatitis B or C with detectable viral nucleic acid, or other clinically significant active viral infection.\n* Uncontrolled cardiovascular disease.\n* Persistent unresolved toxicities greater than CTCAE grade 1 from prior therapy, except alopecia.\n* Gastrointestinal disorders or prior intestinal surgery that may impair oral drug absorption.\n* Pregnancy or breastfeeding.\n* Psychiatric illness or inability to provide informed consent.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for the study.","ALL","18 Years",{"count":20,"type":21},107,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a multicenter, open-label, phase Ib\u002FII study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK\u002FT-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy. In phase Ib, two fixed dose levels of zeprumetostat in combination with tislelizumab will be evaluated to determine the recommended phase II dose (RP2D). In phase II, patients will be enrolled into 2 predefined cohorts according to prior exposure to PD-1 inhibitors to further evaluate efficacy and safety. The primary phase II endpoint is objective response rate at week 12 assessed by independent blinded imaging review according to Lugano 2014 criteria.",[28,29,30],"Extranodal NK\u002FT-cell Lymphoma","NK\u002FT-cell Lymphoma","Relapsed or Refractory NK\u002FT-Cell Lymphoma",[32,33,34,35,36],"Tislelizumab","Zeprumetostat","EZH2 inhibitor","PD-1 inhibitor","NKTCL","RECRUITING","2026-06-16",{"date":40,"type":41},"2026-06-18","ACTUAL",{"date":43,"type":41},"2026-04-30",{"date":45,"type":21},"2028-12-30",{"name":47,"class":48},"Rong Tao","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100605399","early-phase-1-safety-and-efficacy-of-anti-ebv-autologous-tcr-t-cell-injection-in-relapsedrefractory-ebv-positive-lymphoma-100605399","NCT07162012","Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed\u002FRefractory EBV-Positive Lymphoma","The Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection for Treating Relapsed\u002FRefractory EBV-positive Lymphoma Patients With HLA-A11:01","Anti-EBV TCR-T","Inclusion Criteria:\n\n1. Age 18-70 years, male or female.\n2. HLA genotype at locus A is 11:01.\n3. Disease diagnosis and status:\n\n   1. Histologically or cytologically confirmed EBV-positive lymphoma (tumor tissue must be EBER-positive as confirmed by in situ hybridization \\[ISH\\] or fluorescence in situ hybridization \\[FISH\\]), with peripheral blood EBV viral load \\>10³ copies\u002FmL by quantitative real-time PCR.\n   2. Disease types include but are not limited to:\n\n      NK\u002FT-cell lymphoma (NK\u002FTCL); Peripheral T-cell lymphoma (PTCL); Other types.\n   3. Definition of relapse: appearance of new lesions at the primary site or other sites after achieving complete remission (CR).\n   4. Definition of refractory disease (meeting any of the following):\n\n   No partial remission (PR) after ≥4 cycles of standard therapy; No complete remission (CR) after ≥6 cycles of therapy; Failure to achieve CR after autologous hematopoietic stem cell transplantation; If best response is progressive disease (PD) or treatment is discontinued due to PD, no minimum cycle requirement applies.\n4. Prior treatment requirements:\n\n   a) For relapsed\u002Frefractory PTCL or NK\u002FTCL, patients must have received at least one prior line of systemic therapy. For relapsed\u002Frefractory NK\u002FTCL, patients must have received an asparaginase-containing regimen (patients with stage I\u002FII nasal NK\u002FTCL according to the CA staging system must have also received radiotherapy).\n5. Measurable disease: At least one measurable lesion according to the 2014 Lymphoma Response Evaluation Criteria:\n\n   1. Nodal lesions: longest diameter \\>15 mm on contrast-enhanced CT, MRI, or PET-CT;\n   2. Extranodal lesions: longest diameter \\>10 mm. For patients with bone-marrow-only involvement who have no measurable lesions on imaging, the presence of ≥5% lymphoma cells in bone marrow biopsy or flow cytometry can be considered an evaluable lesion.\n6. Adequate organ function, defined as:\n\n   1. Hematologic: absolute neutrophil count ≥1×10⁹\u002FL; hemoglobin ≥70 g\u002FL; platelet count ≥50×10⁹\u002FL;\n   2. Hepatic: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × the upper limit of normal (ULN), and total bilirubin (TBIL) ≤ 1.5 × ULN (except when liver function abnormalities are attributable to the underlying disease);\n   3. Renal: serum creatinine ≤1.5× ULN;\n   4. Cardiac: left ventricular ejection fraction (LVEF) ≥50%;\n   5. Coagulation: fibrinogen ≥1.0 g\u002FL; activated partial thromboplastin time (APTT) ≤1.5× ULN; prothrombin time (PT) ≤1.5× ULN.\n7. Expected survival \\>3 months.\n8. ECOG performance status \\\u003C3.\n9. Contraception requirements:\n\n   1. No pregnancy planned during the treatment period;\n   2. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 4 months after the end of treatment.\n10. Willingness to participate in the study, ability to sign informed consent, comply with the study protocol, and availability of peripheral venous access for lymphocyte collection.\n\nExclusion Criteria:\n\nSubjects meeting any of the following conditions will not be eligible for enrollment:\n\n1. History of other malignancies, except for:\n\n   1. Basal cell carcinoma of the skin;\n   2. Squamous cell carcinoma of the skin;\n   3. Superficial bladder cancer;\n   4. Carcinoma in situ of the cervix;\n   5. Gastrointestinal mucosal carcinoma in situ;\n   6. Other malignancies considered acceptable by the investigator (must have received curative treatment with no recurrence within the past 5 years).\n2. Recent anti-tumor therapy: less than 4 weeks since last anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local therapy), or less than 2 weeks since palliative radiotherapy.\n3. Pregnant or breastfeeding women.\n4. Presence of severe medical conditions such as intracranial hypertension, impaired consciousness, respiratory failure, or disseminated intravascular coagulation (DIC).\n5. Severe organ dysfunction, including:\n\n   NYHA class IV cardiac function; Child-Pugh class C liver function; Creatinine clearance \\\u003C60 mL\u002Fmin (by Cockcroft-Gault formula); Baseline oxygen saturation \\\u003C92%.\n6. Known active infections or positive screening results for:\n\n   1. Hepatitis B virus (HBV): HBsAg positive, or HBcAb positive with HBV-DNA above the detection limit of the study center;\n   2. Hepatitis C virus (HCV): HCV antibody positive and HCV RNA ≥ upper limit of normal (ULN);\n   3. Human immunodeficiency virus (HIV) or Treponema pallidum (syphilis) antibody positive;\n   4. Active tuberculosis (TB) (must be excluded by chest X-ray, sputum test, and clinical symptoms) or history of active TB;\n   5. Severe acute or chronic infections requiring systemic treatment.\n7. Active central nervous system (CNS) disease (e.g., tumor metastasis, infection, demyelinating disease), including untreated lesions, progressive disease on imaging or symptoms requiring urgent intervention, or requiring high-dose immunosuppressive therapy for control.\n8. Receiving systemic corticosteroid therapy prior to screening and judged by the investigator to require long-term systemic corticosteroid treatment during the study (excluding inhaled or topical use); or receiving systemic corticosteroid treatment within 72 hours before cell infusion (excluding inhaled or topical use).\n9. Presence of graft-versus-host disease (GVHD), defined as grade ≥2 acute GVHD or moderate\u002Fsevere chronic GVHD, or current use of immunosuppressive therapy.\n10. History of severe allergic reactions to drugs or excipients required in this study, or history of allergy to tocilizumab.\n11. Any condition that, in the opinion of the investigator, makes the subject unsuitable for study participation.","70 Years",{"count":60,"type":21},24,[62],"EARLY_PHASE1","This study will test whether anti-EBV autologous TCR-T cell injection is safe and effective for patients with relapsed or refractory EBV-positive lymphoma who have HLA-A11:01. Researchers will look at safety, tolerability, and the maximum tolerated dose or recommended dose for future studies.\n\nThe study will also measure how the infused TCR-T cells expand and persist in the body, changes in EBV DNA levels and T-cell subgroups in the blood, and whether the treatment shows early signs of clinical benefit. Researchers will also explore whether the treatment causes an immune response against the infused cells.",[29,65,66],"Peripheral T-cell Lymphoma (PTCL)","DLBCL","2025-11-29",{"date":69,"type":41},"2025-12-02",{"date":71,"type":41},"2025-09-20",{"date":73,"type":21},"2029-09",{"name":75,"class":48},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100592990","phase-2-a-phase-ii-study-of-dexamethasone-azacitidine-pegaspargase-and-tislelizumab-plus-radiotherapy-for-patients-with-stage-iii-extranodal-nkt-cell-lymphoma-100592990","NCT07000617","A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I\u002FII Extranodal NK\u002FT-cell Lymphoma","Inclusion Criteria:\n\n1. Pathologically confirmed diagnosis of extranodal NK\u002FT-cell lymphoma\n2. Age ≥18 years\n3. Ann Arbor stage I or II\n4. Presence of at least 1 measurable lesion according to the 2014 Lugano revised criteria for response assessment\n5. ECOG-PS 0\\~2\n6. Peripheral blood absolute neutrophil count ≥1.5×10E9\u002FL, platelet count ≥75×10E9\u002FL and hemoglobin ≥90g\u002FL\n7. Expected survival of at least 3 months\n8. Capable of understanding the content of this study, agreeing to participate in this study and signing the informed consent.\n\nExclusion Criteria:\n\n1. Unconfirmed pathological diagnosis of NK\u002FT-cell lymphoma\n2. Pregnant or lactating women, or patients of childbearing age unwilling to take contraceptive measures during the study period.\n3. Patients with clinically significant prolonged QTc interval (\\>470ms in males, \\>480ms in females), ventricular tachycardia, atrial fibrillation, second or third degree atrioventricular block, acute myocardial infarction, congestive heart failure, severe or symptomatic coronary artery disease requiring medical treatment.\n4. Patients with large amount of pericardial effusions shown by echocardiogram.\n5. Patients who received supportive care for anemia, neutropenia or thrombocytopenia within 7 days prior to start of study treatment.\n6. Patients with severe active bleeding.\n7. Patients with pulmonary embolism, intracranial hemorrhage or acute cerebral infarction.\n8. Patients with active infectious disease.\n9. Patients who are mentally disabled or unable to understand or sign the informed consent form.\n10. Patients with other conditions judged as ineligible for this study by the investigators.",{"count":83,"type":21},57,[25],"The goal of this clinical trial is to learn if the regimen of dexamethasone, azacitidine, pegaspargase and tislelizumab (DAPT regimen) combined with radiotherapy works to treat stage I or II NK\u002FT cell lymphoma in adults. It will also learn about the safety of the DAPT regimen. The main questions it aims to answer are:\n\nWhat are the efficacy of the DAPT regimen plus radiotherapy in participants with extranodal NK\u002FT-cell lymphoma? What medical problems do participants have when taking the DAPT regimen?\n\nParticipants will:\n\nReceive the DAPT regimen every 21 days for 6 cycles and radiotherapy Visit the clinic according to clinical trial requirement for checkups and tests Receive blood tests and radiological imaging tests according to the clinical trial requirement",[87],"NK\u002FT Cell Lymphoma",[89],"NK\u002FT cell lymphoma","2025-05-24",{"date":92,"type":41},"2025-06-03",{"date":94,"type":41},"2025-03-21",{"date":96,"type":21},"2028-12",{"name":98,"class":48},"Peking University Cancer Hospital & Institute",3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":58,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":49},"100490162","petmr-in-the-staging-and-efficacy-evaluation-of-newly-diagnosed-nkt-cell-lymphoma-100490162","NCT05662540","PET\u002FMR in the Staging and Efficacy Evaluation of Newly Diagnosed NK\u002FT-cell Lymphoma","PET\u002FMR in the Staging and Efficacy Evaluation of Newly Diagnosed NK\u002FT-cell Lymphoma: a Prospective, Single-arm Clinical Study","Inclusion Criteria:\n\n* Pathologically diagnosed NK\u002FT-cell lymphoma based on the WHO classification 2016\n* Age from 14 to 70 years-old\n* ECOG 0-2 score\n* Patients with a life expectancy of at least 6 months\n* Patient has not been treated before for NK\u002FT cell lymphoma\n* Commit to abide by the research procedures and cooperate with the implementation of the whole process of research\n* Written informed consent\n\nExclusion Criteria:\n\n\\- Subjects who meet any of the following criteria are not eligible for study entry\n\n* Diagnosed aggressive NK cell leukemia\n* Pregnant or lactating women\n* Liver and kidney insufficiency\n* Other PET\u002FMR contraindications:\n\n  1. Those with implanted functional electronic devices such as cardiac pacemakers\n  2. Carotid aneurysm clipping and other implants are ferromagnetic materials\n  3. Implanted perfusion devices such as insulin perfusion pumps\n  4. Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients\n  5. Those who are claustrophobic\n* Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study","14 Years",{"count":109,"type":21},40,[111],"NA","This study intends to evaluate the application value of Positron Emission Tomography\u002FMagnetic Resonance (PET\u002FMR) in the staging and efficacy evaluation of NK\u002FT cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.",[29],"2024-10-23",{"date":116,"type":41},"2024-10-26",{"date":118,"type":41},"2023-05-26",{"date":120,"type":21},"2026-10",{"name":122,"class":48},"Ruijin Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":49},"100503333","phase-2-clinical-study-of-xpo1-inhibitor-selinexor-combined-with-copl-in-newly-diagnosed-advanced-nkt-cell-lymphoma-100503333","NCT05833893","Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK\u002FT-cell Lymphoma","Inclusion Criteria:\n\n* Age≥14 years, male or female;\n* Pathologically confirmed newly diagnosed NK\u002FT cell lymphoma according to WHO classification criteria 2016;\n* At least one measurable lesion, defined as bidimensionally measurable, intranodal lesion \\> 1.5 cm in short axis and extranodal lesion \\> 1.0 cm in short axis;\n* ECOG score 0\\~2;\n* Clinical stage III\\~IV;\n* Normal major organ function, meeting the following definitions: Hematology: WBC ≥ 3.5 x 10 9\u002FL, PLT ≥ 75 x 10 9\u002FL, Hb ≥ 80 g\u002FL; Liver and kidney function: AST and ALT ≤ 3.0 ULN; TBIL ≤ 2.0 mg\u002FdL; CCr ≥ 60 mL\u002Fmin; liver and kidney function impairment caused by tumor compression is not limited by this; Fibrinogen: normal at first cycle\n* Expected survival \\> 6 months\n* Agree to use effective contraception;\n* Understand and voluntarily sign written informed consent\n\nExclusion Criteria:\n\n* Prior allogeneic HCT (allo-HCT)\n* Active autoimmune disease\n* Primary central nervous system lymphoma;\n* Patients with infection which requiring treatment. Could be re-enrollment after infection control;\n* Known history of human immunodeficiency virus (HIV) infection\n* Known hypersensitivity to the study drug or any of its excipients;\n* Presence of other active malignancy requiring treatment that could interfere with this study;\n* Patients with other conditions not suitable for enrollment as judged by the investigator.",{"count":130,"type":21},10,[25],"Patients with newly diagnosed, pathologically confirmed NK\u002FT-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.",[134,135,136],"nk\u002FT-cell Lymphoma","Newly Diagnosed","Advanced Lymphoma","2023-04-18",{"date":139,"type":41},"2023-04-27",{"date":141,"type":21},"2023-05-01",{"date":143,"type":21},"2026-12-31",{"name":145,"class":48},"Chinese PLA General Hospital"]